March 24, 2015
A Pennsylvania federal judge on Monday refused to certify a proposed class action accusing drugmaker Cephalon Inc. of unjustly enriching itself by marketing a painkiller for off-label uses, ruling the plaintiffs failed to show that a class action was the best way to resolve their claims.
July 24, 2013
Two entities that pay for employees' prescription drugs on Wednesday asked a Pennsylvania federal judge to certify a class of other purchasers in a suit alleging that drug manufacturer Cephalon Inc. illegally pushed off-label uses for its painkiller Actiq.
October 30, 2012
Two companies that chip in for employees' prescription drugs sought class certification last week in a Pennsylvania suit against Cephalon over off-label marketing for the painkiller Actiq, saying the fact that potentially hundreds of companies had to pay for workers' prescriptions made the case suitable for class treatment.
March 28, 2011
Cephalon Inc. lost a summary judgment bid Wednesday in a Pennsylvania class action claiming the company marketed the cancer pain management drug Actiq for off-label uses and caused third-party payors to pay hundreds of millions of dollars more for prescriptions.